Clean-Revised_Online-Only_Supplemental_Material_Novel_C._HypDas.pdf (391.66 kB)
Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
figure
posted on 2022-03-24, 12:55 authored by Casper K. Nielsen, Caroline C. Øhrstrøm, Urd L. Kielgast, Dorte L. Hansen, Bolette Hartmann, Jens J. Holst, Asger B. Lund, Tina Vilsbøll, Filip K. KnopOBJECTIVE To
investigate the efficacy and safety of dasiglucagon, a novel stable glucagon analog
in a liquid formulation, in Roux-en-Y gastric bypass (RYGB)-operated individuals
suffering from post-bariatric hypoglycemia (PBH).
RESEARCH DESIGN AND METHODS In a randomized, double-blind, placebo-controlled crossover trial, 10 RYGB-operated participants with continuous glucose monitoring (CGM)-verified PBH were randomized to three trial days, each consisting of a 240-minute standardized liquid mixed meal test (MMT) with the subcutaneous injection of either placebo, 80 µg, or 200 µg dasiglucagon.
RESULTS Compared with placebo, treatment with both 80 and 200 µg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L (mean ± standard error of the mean (SEM)); 80 µg dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 µg dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG < 3.9 mmol/L) by 70.0 minutes (P = 0.030 and P = 0.008).
CONCLUSION Single-dose administration of dasiglucagon effectively mitigated postprandial hypoglycemia.
